Relmada Therapeutics (RLMD) Stock Forecast & Price Target

RLMD$4.21+0.05 +1.20%
BiotechnologyGrowth Stock
Compare
Market cap$449.19MEnterprise value$432.41MRevenue (TTM)$0Market position—

Score

68
Bullish
Value
57
Quality
47
Growth
100

Relmada Therapeutics, Inc. price target

RLMD
Low$12.00
Average$12.00
High$12.00
Upside vs current price+185.0%

The average target of $12.00 is +185.0% versus the current RLMD price of $4.21.

Relmada Therapeutics, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy3
Hold0
Sell0
Strong sell0
ConsensusBuy

4 analysts cover RLMD.

Relmada Therapeutics, Inc. EPS and revenue estimates

RLMD shows the next fiscal years with at least three analysts: 2026 EPS $-0.62, 2027 EPS $-0.80. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$-0.62$10.00M
2027$-0.80$32.45M

Is Relmada Therapeutics, Inc. a buy or sell?

Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a buy (1 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The RLMD consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.

The average target of $12.00 implies +185.0% versus the current price of $4.21.

Those 4 ratings on RLMD are a headcount, and the label on file is Buy.

Reading the Relmada Therapeutics, Inc. forecast

The RLMD targets sit in a narrow band, from $12.00 to $12.00, around an average of $12.00.

Set next to the $4.21 RLMD quote, that average is +185.0%.

Ratings on the Relmada Therapeutics, Inc. cluster: 4 of 4 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

The RLMD EPS path from 2026 ($-0.62) to 2027 ($-0.80) is falling.

Only 4 analysts cover RLMD, so the average rests on a short list.

Relmada Therapeutics, Inc. forecast questions

What is the RLMD price target?

The published range for RLMD is $12.00 to $12.00, with an average of $12.00. That average is +185.0% versus the current price of $4.21.

Is Relmada Therapeutics, Inc. a buy or sell?

Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the RLMD headcount is 4 buy, 0 hold, and 0 sell.

What is the EPS estimate for Relmada Therapeutics, Inc.?

Analyst EPS estimates for Relmada Therapeutics, Inc.: 2026 $-0.62, 2027 $-0.80.

What is the revenue estimate for Relmada Therapeutics, Inc.?

Analyst revenue estimates for Relmada Therapeutics, Inc.: 2026 $10.00M, 2027 $32.45M.

How many analysts cover RLMD?

4 analysts cover RLMD. Their consensus on RLMD is Buy, across those 4.

RLMD price $4.21 +0.05 +1.20%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener